下一代糖尿病藥物輸送市場規模、佔有率和成長分析（按產品、人口統計、適應症、最終用戶和地區分類）—2026-2033年產業預測

全球下一代糖尿病藥物輸送市場預計到 2024 年將達到 393.1 億美元，到 2025 年將達到 425.8 億美元，到 2033 年將達到 805.7 億美元，預測期（2026-2033 年）的複合年成長率為 8.3%。

受全球糖尿病盛行率不斷上升的推動，新一代糖尿病藥物傳輸系統的全球市場正經歷強勁成長。市場對兼具有效性、便利性和微創性的創新治療方法有著顯著的需求。治療重點正從單純控制血糖轉向促進減重、改善心血管健康和提升整體生活品質的治療方法，這推動了廣泛的研發投入。然而，挑戰依然存在，例如這些先進治療方法和設備的高成本，嚴重阻礙了醫保報銷和患者的可及性。此外，漫長而高成本的監管核准流程也構成了另一道障礙，而真正實現非侵入性或可靠的「閉合迴路」系統仍然是糖尿病綜合管理面臨的一項重大技術挑戰。

推動全球下一代糖尿病藥物傳遞市場發展的因素

全球新一代糖尿病藥物傳輸市場的顯著擴張主要受1型和2型糖尿病患者數量大幅成長的驅動。不斷成長的患者群體需要更有效率、更便捷的治療方案，從而催生了對創新治療解決方案的巨大需求。隨著越來越多的人尋求有效控制病情的方法，對高效且能改善患者體驗的先進藥物輸送系統的需求日益迫切。糖尿病盛行率的持續上升凸顯了該領域發展的迫切性，推動了市場的不斷進步和發展機會。

全球下一代糖尿病藥物輸送市場面臨的限制因素

全球新一代糖尿病藥物輸送市場面臨的主要挑戰之一是治療方法和醫療設備的高成本，這往往超出了許多患者的經濟承受能力。這種經濟負擔阻礙了患者獲得治療，尤其是在新興市場，因為在這些地區，從公共和私人保險公司獲得報銷極其困難。因此，保險覆蓋範圍的限制使得患者無法獲得必要的治療，最終限制了治療選擇，並加劇了糖尿病治療的不平等。這些經濟限制對創新糖尿病治療方法的廣泛應用構成了重大障礙。

下一代糖尿病治療藥物傳遞的全球市場趨勢

全球下一代糖尿病藥物輸送市場正日益受到醫療設備間互通性和互聯性的推動。患者在將持續血糖監測 (CGM) 設備與胰島素幫浦配合使用時，越來越希望獲得個人化的體驗，這推動了對開放式通訊協定系統的需求。這一趨勢提高了糖尿病管理的柔軟性和使用者控制權，並透過個人化治療促進了更好的治療效果。隨著醫療保健朝向更一體化的數位化環境發展，製造商正在投資開發智慧、擴充性的解決方案，以實現設備間的無縫通訊。這種技術融合不僅賦予病人更多自主權，也推動了市場創新和競爭格局的演變。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球下一代糖尿病藥物傳輸市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 吸入式胰島素
• 口服胰島素
• 胰島素貼劑
• CGM系統
• 人工胰臟

全球下一代糖尿病藥物傳輸市場規模（按人口統計和複合年成長率分類）（2026-2033 年）

• 成年人口（14歲以上）
• 兒童人口（14歲以下）

全球下一代糖尿病藥物傳輸市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 1型糖尿病
• 2型糖尿病

全球下一代糖尿病藥物傳輸市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 診斷/診所
• 加護病房（ICU）
• 家庭醫療保健

全球下一代糖尿病藥物傳輸市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk A/S（Denmark）
• Medtronic Plc（Ireland）
• Abbott Laboratories（United States）
• Dexcom, Inc.（United States）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Insulet Corporation（United States）
• Tandem Diabetes Care, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• MannKind Corporation（United States）
• Becton, Dickinson and Company（BD）（United States）
• Ypsomed AG（Switzerland）
• Senseonics Holdings, Inc.（United States）
• Diabeloop SAS（France）
• Beta Bionics, Inc.（United States）
• Embecta Corp.（United States）
• Biocon Limited（India）
• Nemaura Medical Inc.（United Kingdom）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）

結論與建議

Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 39.31 Billion in 2024 and is poised to grow from USD 42.58 Billion in 2025 to USD 80.57 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The global market for next-generation diabetes therapy and drug delivery is experiencing robust growth fueled by the rising prevalence of diabetes worldwide. There exists a significant demand for innovative treatments that prioritize effectiveness, convenience, and minimal invasiveness. The focus is shifting from mere glucose management to therapies that promote weight loss, enhance cardiovascular health, and improve overall quality of life, driving extensive research and development initiatives. Nonetheless, challenges persist, including the high costs associated with these advanced therapies and devices, which present significant reimbursement and access hurdles. Additionally, navigating the lengthy and costly regulatory approval processes poses further obstacles, while the pursuit of truly non-invasive or reliable "closed loop" systems remains a technical challenge critical for comprehensive diabetes management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Diabetes Therapy Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Diabetes Therapy Drug Delivery Market Segments Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Diabetes Therapy Drug Delivery Market

The remarkable expansion of the global diabetes therapy drug delivery market is primarily driven by the significant increase in the number of people diagnosed with Type 1 and Type 2 diabetes. This growing population of patients necessitates enhanced and more convenient management options, creating a substantial demand for innovative therapeutic solutions. As more individuals seek effective ways to manage their condition, the need for advanced drug delivery systems that offer greater efficiency and improved patient experiences becomes increasingly critical. The ongoing rise in diabetes prevalence underscores the urgency for development in this sector, fueling ongoing advancements and opportunities within the market.

Restraints in the Global Next Generation Diabetes Therapy Drug Delivery Market

One significant challenge facing the Global Next Generation Diabetes Therapy Drug Delivery market is the high cost of therapies and devices, which often surpasses the financial capabilities of many patients. This economic burden creates a barrier to access, particularly in emerging markets where securing reimbursement from public and private payers proves to be incredibly difficult. As a result, the limited availability of insurance coverage hampers the ability of patients to obtain essential treatments, ultimately restricting their options and increasing disparities in diabetes care. These financial constraints pose a considerable obstacle to the widespread adoption of innovative diabetes therapies.

Market Trends of the Global Next Generation Diabetes Therapy Drug Delivery Market

The global next-generation diabetes therapy drug delivery market is increasingly shaped by the surge in interoperability and connectivity among medical devices. Patients are seeking more personalized experiences by combining continuous glucose monitors (CGMs) with insulin pumps, which fosters the demand for open-protocol systems. This trend enhances flexibility and user control in diabetes management, promoting better outcomes through tailored therapies. As healthcare moves toward a more integrated digital landscape, manufacturers are investing in smart, scalable solutions that facilitate seamless communication between devices. This convergence of technology not only empowers patients but also drives innovation and competitive dynamics within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Product & CAGR (2026-2033)

• Market Overview
• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Demographic & CAGR (2026-2033)

• Market Overview
• Adult Population (>14years)
• Child Population (14years)

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes

Global Next Generation Diabetes Therapy Drug Delivery Market Size by End User & CAGR (2026-2033)

• Market Overview
• Diagnostic/Clinics
• ICUs
• Home Healthcare

Global Next Generation Diabetes Therapy Drug Delivery Market Size & CAGR (2026-2033)

• North America (Product, Demographic, Indication, End User)
  • US
  • Canada
• Europe (Product, Demographic, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Demographic, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Demographic, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Demographic, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SAS (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Embecta Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nemaura Medical Inc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations